Pibrentasvir: Difference between revisions

From WikiMD's Wellness Encyclopedia

Newer edit →
Created page with " {{intro}} Mavyret is an oral, fixed combination of antiviral agents used to treat chronic hepatitis C virus (HCV) infection due to any genotype (1 through 6). {{livtox}} Th..."
 
CSV import
Line 1: Line 1:
{{Short description|An antiviral medication used in the treatment of hepatitis C}}
{{Drugbox
| image = Pibrentasvir.svg
| image_size = 250px
| image_alt = Chemical structure of Pibrentasvir
}}


{{intro}}
'''Pibrentasvir''' is an [[antiviral drug]] used in combination with other medications for the treatment of [[hepatitis C virus]] (HCV) infection. It is a component of the fixed-dose combination drug [[Glecaprevir/pibrentasvir]], marketed under the brand name Mavyret.
Mavyret is an oral, fixed combination of antiviral agents used to treat chronic hepatitis C virus (HCV) infection due to any genotype (1 through 6).  


{{livtox}}
==Mechanism of Action==
This combination has not been linked to instances or worsening of serum enzymes during therapy or with de novo appearance of clinically apparent [[liver injury]]. However, all effective direct acting antiviral agents for hepatitis C are considered capable of causing reactivation of hepatitis B in susceptible patients.
Pibrentasvir is a [[NS5A inhibitor]], which means it targets the nonstructural protein 5A (NS5A) of the hepatitis C virus. NS5A is essential for viral replication and assembly, and by inhibiting this protein, pibrentasvir disrupts the life cycle of the virus, thereby reducing viral load in the patient's body.


{{moa}}
==Pharmacokinetics==
Mavyret is the commercial name for a fixed combination of oral antiviral agents used to treat chronic hepatitis C virus infection of all genotypes (1 through 6). The hepatitis C virus encodes several nonstructural (NS) polypeptides that are essential for its replication, including NS3/4 that has protease and helicase activities, NS5A that is a membrane bound polypeptide that is essential for viral replication and NS5B an HCV specific, RNA-dependent, RNA polymerase. These polypeptides are effective targets for antiviral therapy of hepatitis C. Mavyret is a fixed dose combination of glecaprevir (glek a' pre vir) which is a potent HCV NS3/4 protease inhibitor and pibrentasvir (pi brent' as vir) an HCV NS5A inhibitor. In cell culture, each of these agents has potent activity against all genotypes of HCV, but antiviral resistance can arise rapidly with continued exposure to a single agent. The combination of several direct acting agents with different molecular targets allows for a sustained viral suppression while avoiding antiviral resistance. The combination of glecaprevir and pibrentasvir was shown to be very effective in suppressing HCV replication in patients infected with all 6 HCV genotypes and to result in sustained virological responses (SVR) and eradication of HCV in more than 95% of patients when given for 8 weeks or more.  
Pibrentasvir is administered orally and is highly bioavailable. It is extensively metabolized in the liver and excreted primarily in the feces. The drug has a long half-life, allowing for once-daily dosing when used in combination with other antiviral agents.


{{fda}}
==Clinical Use==
{{PAGENAME}} was approved for use in the United States in 2017, the fifth all-oral antiviral combination to receive approval for chronic hepatitis C. It is available as tablets in a fixed dose combination of 100 mg of glecaprevir and 40 mg of pibrentasvir. The recommended dose in adults is 3 tablets once daily for 8 weeks in patients without cirrhosis and for 12 weeks in those with compensated (Class A) cirrhosis. Longer courses of therapy (12 or 16 weeks) are also recommended for patients previously treated with HCV NS3/4 protease inhibitors or NS5A inhibitors. It has not been approved for use in patients with decompensated cirrhosis.  
Pibrentasvir is used in combination with [[glecaprevir]], a [[NS3/4A protease inhibitor]], to treat adults with chronic hepatitis C virus infection. This combination is effective against all major genotypes of HCV, making it a [[pan-genotypic]] treatment option. The typical treatment duration is 8 to 12 weeks, depending on the patient's prior treatment history and the presence of cirrhosis.


{{se}}
==Side Effects==
Side effects are uncommon but are generally mild and can include fatigue, [[headache]] and [[nausea]].
Common side effects of pibrentasvir, when used in combination with glecaprevir, include headache, fatigue, and nausea. Serious side effects are rare but may include liver enzyme elevations and hypersensitivity reactions.
{{hepatitis c drugs}}
 
{{coststubd}}
==Contraindications==
Pibrentasvir is contraindicated in patients with severe hepatic impairment (Child-Pugh C) and in those with known hypersensitivity to the drug or any of its components. Caution is advised when used in patients with moderate hepatic impairment (Child-Pugh B).
 
==Related pages==
* [[Hepatitis C virus]]
* [[Antiviral drug]]
* [[NS5A inhibitor]]
* [[Glecaprevir/pibrentasvir]]
 
[[Category:Antiviral drugs]]
[[Category:Hepatitis C]]

Revision as of 10:49, 15 February 2025

An antiviral medication used in the treatment of hepatitis C


Pibrentasvir
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG


Pibrentasvir is an antiviral drug used in combination with other medications for the treatment of hepatitis C virus (HCV) infection. It is a component of the fixed-dose combination drug Glecaprevir/pibrentasvir, marketed under the brand name Mavyret.

Mechanism of Action

Pibrentasvir is a NS5A inhibitor, which means it targets the nonstructural protein 5A (NS5A) of the hepatitis C virus. NS5A is essential for viral replication and assembly, and by inhibiting this protein, pibrentasvir disrupts the life cycle of the virus, thereby reducing viral load in the patient's body.

Pharmacokinetics

Pibrentasvir is administered orally and is highly bioavailable. It is extensively metabolized in the liver and excreted primarily in the feces. The drug has a long half-life, allowing for once-daily dosing when used in combination with other antiviral agents.

Clinical Use

Pibrentasvir is used in combination with glecaprevir, a NS3/4A protease inhibitor, to treat adults with chronic hepatitis C virus infection. This combination is effective against all major genotypes of HCV, making it a pan-genotypic treatment option. The typical treatment duration is 8 to 12 weeks, depending on the patient's prior treatment history and the presence of cirrhosis.

Side Effects

Common side effects of pibrentasvir, when used in combination with glecaprevir, include headache, fatigue, and nausea. Serious side effects are rare but may include liver enzyme elevations and hypersensitivity reactions.

Contraindications

Pibrentasvir is contraindicated in patients with severe hepatic impairment (Child-Pugh C) and in those with known hypersensitivity to the drug or any of its components. Caution is advised when used in patients with moderate hepatic impairment (Child-Pugh B).

Related pages

Retrieved from "https://wikimd.com/index.php?title=Pibrentasvir&oldid=6293189"